Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Time to Buy?

Posted by Stanley Muller on Sep 8th, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $42.02 and last traded at $41.30, with a volume of 493228 shares traded. The stock had previously closed at $35.25.

Wall Street Analyst Weigh In

Several research firms recently commented on PHVS. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Guggenheim lifted their price target on Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Morgan Stanley lifted their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a report on Thursday, June 25th. HSBC raised shares of Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Finally, Royal Bank Of Canada raised their price objective on shares of Pharvaris from $51.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.08.

Check Out Our Latest Stock Analysis on PHVS

Pharvaris Stock Up 14.3%

The business’s 50-day simple moving average is $34.79 and its 200-day simple moving average is $31.12. The stock has a market cap of $2.64 billion, a PE ratio of -13.21 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts anticipate that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Berndt Modig sold 2,292 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at approximately $4,541,831.25. This represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 118,655 shares of company stock worth $4,188,002 in the last 90 days.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Pharvaris in the 2nd quarter worth $41,000. CoreCap Advisors LLC bought a new stake in Pharvaris during the second quarter valued at about $93,000. Barclays PLC purchased a new position in Pharvaris in the fourth quarter valued at about $77,000. JPMorgan Chase & Co. raised its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Pharvaris in the fourth quarter worth about $139,000.

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.